We report two AIDS patients who developed acute renal failure while receiving sulphadiazine for cerebral toxoplasmosis. Renal ultrasound revealed diffuse bilateral echogenic shadowing material. 'Sheaves ofwheat' crystals, typical of sulphadiazine crystalluria, were present in the urine. One patient required a percutaneous nephrostomy. Hydration and urine alkalinisation resulted in rapid improvement of renal function and ultrasonographic findings. Sulphadiazine-induced crystailuria and acute renal failure is increasingly frequent. Awareness of its existence may lead to prevention and early conservative treatment.
Sulphonamides are among the drugs that may precipitate in acid urine and give rise to crystalluria and calculi. In recent years, sulphadiazine, in association with pyrimethamine, has become standard therapy for cerebral toxoplasmosis, a frequent complication of the acquired immune deficiency syndrome (AIDS) and other immunodeficiency states.' The progression of the AIDS epidemic has been accompanied by an increased use of sulphadiazine, and a re-emergence of its adverse effects. Renal failure is one of these 'forgotten' complications. 2 Case 1 An HIV-positive 31-year-old man presented with vomiting, left flank pain that radiated to the groin, oligoanuria and dark urine. An evaluation one month before admission for fever and right hemiparesis disclosed an intracerebral mass suggestive of cerebral toxoplasmosis. Sulphadiazine (1 g/6 h), pyrimethamine (25 mg/day), and folinic acid were begun seven days before admission. At that time renal function was normal (serum creatinine 88 jimol/l).
On admission, his body temperature was 36°C and blood pressure 120/80 mmHg. Significant initial laboratory values were: creatinine 858 ,umol/l, urea 22 ,umol/l. Urinalysis revealed gross haematuria, and many crystals with a characteristic 'sheaves of wheat' morphology (figure 1). A plain abdominal X-ray showed normal-sized kidneys with no evidence of calculi. Renal ultrasound demonstrated bilateral multiple diagnostic echogenic foci with shadowing consistent with calculi. There was no hydronephrosis. Diuresis for the first 24 hours was 200 ml.
Sulphadiazine was discontinued and he was intravenously hydrated with 1/6 M NaHCO, and 0.9% sodium chloride. After 24 h he was challenged with 250 mg furosemide intravenously, and diuresis over the next 24 hours was 6 1. Urine pH was 7.5. Renal function improved rapidly over the next several days. On day 8, urea was 3.8 yumol/l; creatinine 92 4umol/ 1, and a repeat ultrasound revealed absence of calculi.
Case 2 A 57-year-old man presented with abdominal pain, dysuria and oligoanuria. One month before admission he had been diagnosed as having AIDS and cerebral toxoplasmosis, and had been discharged three days earlier on sulphadiazine (1.5 g/6 h), pyrimethamine (25 mg/day), and folinic acid.
On admission, his body temperature was 37.30C and blood pressure 140/80 mmHg.
Initial laboratory values were: creatinine 619 ,umol/l, urea 21 yimol/l. Urinalysis revealed haematuria and 'sheaves of wheat' crystals. A simple abdominal X-ray showed normal-sized kidneys with no evidence of calculi. Renal ultrasound demonstrated bilateral multiple echogenic foci with shadowing consistent with calculi, and minimal bilateral dilatation of the renal pelvis (figure 2). Sulphadiazine was discontinued. Intravenous hydration with 1/ 6 M NaHCO, and 0.9% sodium chloride was begun, but the patient remained anuric for the Thereafter, renal function and urinary output improved rapidly. On day 6, creatinine was 132 jumol/l, and a repeat ultrasound revealed absence of calculi.
Discussion
Obstructive renal failure associated with sulphadiazine has been recognised since the 1940s.'4 However, with the advent of newer, safer antibiotics, this complication all but disappeared from the medical literature, only to re-emerge in the wake of the AIDS epidemic."5'6 Sulphonamides precipitate in the urinary tract due to their low solubility in acid media, especially in the presence of dehydration and hypoalbuminaemia,6 two conditions that are common in AIDS patients. Sulphadiazine has a relatively low urine solubility, so that for the usual daily dose of 4 g, approximately 16 1 of urine at a pH of 5.5 need to be produced to keep the drug in solution. 2 The amount of sulphadiazine excreted without crystallisation can be increased more than 20-fold by increasing urinary pH from 5.5 to 7.5.3
Renal toxicity usually develops after three days of sulphadiazine therapy, although it has been reported following a single large dose.2 Sulphadiazine crystalluria should be suspected when acute renal failure develops in patients receiving sulphadiazine, especially if there are symptoms of renal colic. Confirmation of the diagnosis requires demonstration of radiolucent urinary lithiasis by ultrasound and plain abdominal X-ray,7 as well as urinalysis that 
